Literature DB >> 8497887

Liver biopsy. Its safety and complications as seen at a liver transplant center.

D H Van Thiel1, J S Gavaler, H Wright, A Tzakis.   

Abstract

Liver biopsy is a frequently utilized diagnostic tool at a liver transplant center. It is occasionally utilized prior to OLTx to determine whether or not a potential recipient either has tumor or a disease process that has some chance of spontaneous recovery without OLTx. Following OLTx, it is often utilized to determine the need to alter a recipient's immunosuppression regimen or gauge the response to a recent change in immunosuppression. At the University of Pittsburgh Medical Center, adult liver transplant patients have been biopsied using 3 different techniques based upon the physician's (Tru-cut needle) or surgeon's (suction needle) personal choice and whether or not it has been the intent of the biopsy to obtain tissue from a focal lesion within a liver. In the latter cases, ultrasound guidance and an automated biopsy needle are used. In the former, either a suction-type needle (Jamshidi) or a cutting needle (Tru-cut) has been used. During the period between January 1, 1989, and December 31, 1991, a total of 12,750 liver biopsies have been done on patients admitted to the adult transplant service at this institution. Of these, 8500 were performed with a suction needle, 4195 were performed using a cutting needle, and 55 were performed under ultrasound guidance using an automated cutting needle. A total of 26 major complications occurred--19 with the suction needle (0.22%); 6 with the cutting needle (0.14%), and 2 using ultrasound guidance and an automatic cutting needle (3.6%). Nine of these 26 complications required surgical intervention consisting of a thoracotomy or laparotomy; 4 required the insertion of a chest tube and two required hepatic artery embolization. Based upon these data obtained at a large transplant center, it can be concluded that, in general: (1) a liver biopsy can be done safely in liver transplant recipients; (2) an overall low rate of major complications occurs varying from 0.1 to 3.6% depending upon the type of needle and other circumstances relating to the biopsy procedure; (3) complications, when they occur, are morbid and often necessitate either additional surgical or interventional radiologic procedures.

Entities:  

Mesh:

Year:  1993        PMID: 8497887     DOI: 10.1097/00007890-199305000-00029

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  31 in total

1.  Liver biopsy in liver transplant recipients.

Authors:  Thuong G Van Ha
Journal:  Semin Intervent Radiol       Date:  2004-12       Impact factor: 1.513

2.  Liver biopsy: is the pain for real or is it only the fear of it?

Authors:  Sinan Akay; Zeki Karasu; Aysin Noyan; Semanur Pala; Ahmet Musoglu; Tankut Ilter; Yucel Batur
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

3.  Comparison of noninvasive models of fibrosis in chronic hepatitis B.

Authors:  S C Raftopoulos; J George; M Bourliere; E Rossi; W B de Boer; G P Jeffrey; M Bulsara; D J Speers; G MacQuillan; H L I Ching; N Kontorinis; W Cheng; J Flexman; S Fermoyle; P Rigby; L Walsh; D McLeod; L A Adams
Journal:  Hepatol Int       Date:  2011-07-12       Impact factor: 6.047

4.  Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis.

Authors:  Katherine E McGoogan; P Brian Smith; Steve S Choi; Wallace Berman; Ravi Jhaveri
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-03       Impact factor: 2.839

5.  Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.

Authors:  E S Andersen; M Ruhwald; B Moessner; P B Christensen; O Andersen; J Eugen-Olsen; N Weis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-13       Impact factor: 3.267

Review 6.  Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis.

Authors:  Basile Njei; Thomas R McCarty; Jeffrey Luk; Oforbuike Ewelukwa; Ivo Ditah; Joseph K Lim
Journal:  J Gastroenterol Hepatol       Date:  2016-10       Impact factor: 4.029

7.  Percutaneous liver biopsy after living donor liver transplantation resulting in fulminant hepatic failure: the first reported case of hepatic compartment syndrome.

Authors:  Nicholas N Nissen; Stephen A Geller; Andrew Klein; Steve Colquhoun; David Yamini; Tram T Tran; Benjamin Weinberg; Julie Winn; Fred Poordad
Journal:  J Transplant       Date:  2010-04-08

8.  Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London.

Authors:  I T Gilmore; A Burroughs; I M Murray-Lyon; R Williams; D Jenkins; A Hopkins
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

9.  Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.

Authors:  E S Andersen; S Rødgaard-Hansen; B Moessner; P B Christensen; H J Møller; Nina Weis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-10       Impact factor: 3.267

Review 10.  Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C.

Authors:  Rudolf-E Stauber; Carolin Lackner
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.